FDA unveils guidance aimed at curbing REMS abuse

FDA released new guidance documents Thursday that are intended to curtail the abuse of REMS to stall generic competition. The guidances clarify the requirements for REMS when they are to be shared by both branded and generic drugs, and outline the

Read the full 417 word article

User Sign In